Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.51 |
| ▸ | DHFR | P00374 | 3/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.49 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5124906 | 0.86 | DHFR (0.50) | USP7DHFR | |
| SCHEMBL264111 | 0.85 | HRH3 (0.56) | USP7LRRK2PIK3CDDHFR | |
| SCHEMBL4937481 | 0.80 | USP7 (0.54) | USP7LRRK2NCF1PIK3CDCNR1 | |
| SCHEMBL4611806 | 0.79 | DHFR (0.71) | DHFR | |
| SCHEMBL14988278 | 0.76 | NCF1 (0.53) | USP7LRRK2NCF1PIK3CDCNR1 | |
| SCHEMBL18066751 | 0.74 | USP7 (1.00) | USP7 | |
| SCHEMBL29586142 | 0.74 | USP7 (1.00) | USP7 | |
| SCHEMBL1690875 | 0.73 | ALDH1A1 (0.66) | NCF1CNR1CNR2PSMB8 | |
| SCHEMBL16054137 | 0.73 | NCF1 (0.60) | USP7LRRK2NCF1CNR1CNR2 | |
| SCHEMBL1612996 | 0.73 | PIK3CA (0.44) | LRRK2DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| CN-103626742-A | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC | 2014-03-12 | — | — | CN | disclosed |
| CN-101370792-B | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC | 2013-03-20 | — | — | CN | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| CN-101370792-A | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN INC (US) | 2009-02-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | USP7 3443/4885LRRK2 490/4885NCF1 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.